Nice commentary on ODAC review of sotorasib by Melissa L. Johnson Sarah Cannon Docs at #TexasLung24 important lessons for future trial design.
The treatment landscape for KRAS mutant NSCLC is rapidly evolving. Currently approved drugs include sotorasib and adagrasib (for previously treated KRAS G12C NSCLC). Several trials (1st line, combination, newer agents) are underway. Great talk by Melissa L. Johnson. #TexasLung24
#AmgenPharmaceuticals
#Lumakras
#Sotorasib
#Lumakras 320mg
#Lumakras 120mg
#索托拉西布
#lungcancer
#NSCLC
#cancermedicine
Website: medicine-international.com
Hoy hemos estado hablando sobre Sotorasib un CPNCP KRAS G12C. Las curvas no son las de una mutación driver, pero un 25% de pacientes sin progresar al año y un 85% de DCR, con un perfil de toxicidad manejable, lo convierten en una opción clara en 2L frente a Docetaxel. Amgen España
Alessandro Cosentino Michael Nielsen Scott Alexander Our World in Data Iñigo San Millán respectfully, that's an ignorant take
drugs like sotorasib, osimertinib, larotrectinib were only feasible after massive cancer genomics studies in TCGA
the idea that the field relies on massive KM-curve trials to advance is 20 years out of date, look at I-SPY-2 adaptive trials
